Abstract | INTRODUCTION: METHODS: Total 85 patients with PD and 91 healthy controls finally completed all assessments. The severity of panic symptoms and whole anxiety of PD was measured by Panic Disorder Severity Scale-Chinese Version (PDSS-CV) and Hamilton Anxiety Scale (HAMA-14). Montreal Cognitive Assessment (MoCA) and some neurocognitive measures were conducted to evaluate the cognitive performance. All participants were detected for the plasma BDNF levels and BDNF Val66Met polymorphism before assessment and treatment. RESULTS: No significant differences were found in the BDNF allele frequencies and the BDNF genotype distributions between healthy controls and PD patients. BDNF Met/Met genotype was associated with lower BDNF plasma levels in PD patients, and PD patients with BDNF Met/Met genotype had the lower scores in the attention and speed of processing domains compared to those with Val/Val and Met/Val genotype (p's < .05). Among PD patients, the BDNF plasma levels showed moderate positive correlations with Stroop interference (r = .60, p < .001). Using the MoCA data, the BDNF plasma levels were correlated with delayed memory (r = .50, p < .001), verbal learning (r = .45, p < .001), and total scores of MoCA (r = .51, p < .001). CONCLUSIONS:
|
Authors | Wenchen Wang, Yuanyuan Liu, Shuqing Luo, Xiaoyun Guo, Xingguang Luo, Yong Zhang |
Journal | Brain and behavior
(Brain Behav)
Vol. 10
Issue 12
Pg. e01885
(12 2020)
ISSN: 2162-3279 [Electronic] United States |
PMID | 33047489
(Publication Type: Journal Article)
|
Copyright | © 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC. |
Chemical References |
- Brain-Derived Neurotrophic Factor
- BDNF protein, human
|
Topics |
- Brain-Derived Neurotrophic Factor
(genetics)
- Cognitive Dysfunction
(genetics)
- Genotype
- Humans
- Panic Disorder
(genetics)
- Polymorphism, Genetic
- Polymorphism, Single Nucleotide
|